Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Prior treatment

• Received extensive radiotherapy within 4 weeks of treatment
• Received close distance radiotherapy within 60 days
• Major surgery within 4 weeks of treatment

Other illness

• Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have small possibility of recurrence. Patients with radically treated carcinoma in situ (non-infiltrating) and skin cancer other than malignant melanoma can be enrolled;
• Active HIV infection
• Active Hepatitis B or C infection

Lab values

• Having received antitumor therapy (including chemotherapy, hormone therapy, biotherapy, immunotherapy or traditional Chinese medicine for antitumor indication) within 3 weeks prior to the start of study treatment, or having received treatment with small molecular tyrosine kinase inhibitors (e.g., EGFR-TKI) within 2 weeks prior to the start of study treatment;

Other

• Taken strong CYP3A4 inducer within 2 weeks
• Not recovered from past anti-tumor treatment toxicity

• Fully aware this study and signed the informed consent form in voluntary manner, and willing and able to comply with the study procedure;
• Age ≥18 years;
• Histologically diagnosed locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma
• MET gene amplifications
• Cohort 1 \& 3: Having measurable lesions (in accordance with RECIST 1.1 criteria); Cohort 2: having evaluable lesions
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
• Survival is expected to exceed 12 weeks;
• Adequate functionality in bone marrow, liver, kidney
• Able to take or swallow the drug orally.
• Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug, The male patients whose sexual partners are women of childbearing age must use condom during sexual intercourse during the study and within 6 months after discontinuation of study drug;